Keros Therapeutics, Inc. (KROS) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
KROS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
KROS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 99.4% | 28.9% | 35.7% |
| 2024 | 100.0% | -5939.0% | -5277.5% |
| 2023 | 100.0% | -112543.7% | -101319.2% |
| 2022 | - | - | - |
| 2021 | 100.0% | -280.5% | -292.3% |
Download Data
Export KROS earnings history in CSV or JSON format
Free sign-in required to download data
Keros Therapeutics, Inc. (KROS) Earnings Overview
As of May 8, 2026, Keros Therapeutics, Inc. (KROS) reported trailing twelve-month net income of $87M, reflecting +146.0% year-over-year growth. The company earned $2.30 per diluted share over the past four quarters, with a net profit margin of 35.7%.
Looking at the long-term picture, KROS's historical earnings data spans multiple years. The company achieved its highest annual net income of $87M in fiscal 2025, representing a new all-time high.
Keros Therapeutics, Inc. maintains industry-leading profitability with a gross margin of 99.4%, operating margin of 28.9%, and net margin of 35.7%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including IMVT (-$464M net income), KRYS ($225M net income, 52.6% margin), DAWN (-$107M net income, -67.8% margin), KROS has comparable earnings metrics. Compare KROS vs IMVT →
KROS Earnings vs Peers
Earnings metrics vs comparable public companies
KROS Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $87M | +146.4% | $71M | $2.30 | 35.7% | 28.9% |
| 2024 | -$187M | -22.5% | -$211M | $-5.00 | -5277.5% | -5939.0% |
| 2023 | -$153M | -46.2% | -$170M | $-5.20 | -101319.2% | -112543.7% |
| 2022 | -$105M | -78.2% | -$115M | $-4.15 | - | - |
| 2021 | -$59M | -29.5% | -$56M | $-2.52 | -292.3% | -280.5% |
| 2020 | -$45M | -267.5% | -$47M | $-2.93 | - | - |
| 2019 | -$12M | -824.6% | -$11M | $-1.39 | -123.4% | -105.6% |
| 2018 | -$1M | - | -$2M | $-0.15 | -13.4% | -16.9% |
See KROS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KROS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KROS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKROS — Frequently Asked Questions
Quick answers to the most common questions about buying KROS stock.
Is KROS growing earnings?
KROS EPS is $2.30, with earnings growth accelerating to +146.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $87M.
What are KROS's profit margins?
Keros Therapeutics, Inc. net margin is +35.7%, with operating margin at +28.9%. Above-average margins indicate pricing power.
How consistent are KROS's earnings?
KROS earnings data spans 2018-2025. The accelerating earnings trend is +146.0% YoY. Historical data enables comparison across business cycles.